SYBX Share Price Performance
US$1.69
0.26 (18.18%)
Price US$1.69
Share PriceUS$1.69
Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth
Sep 18
Synlogic, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
SYBX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Synlogic, Inc. Key Details
About SYBX
- Founded
- n/a
- Employees
- 1
- CEO
- WebsiteView website
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
